title: The chimeric transcript RUNX1-GLRX5: a biomarker for good postoperative prognosis in Stage IA non-small-cell lung cancer.
abstract: Stage IA non-small-cell lung cancer cases have been recognized as having a low risk of relapse; however, occasionally, relapse may occur. To predict clinical outcome in Stage IA non-small-cell lung cancer patients, we searched for chimeric transcripts that can be used as biomarkers and identified a novel chimeric transcript, RUNX1-GLRX5, comprising RUNX1, a transcription factor, and GLRX5. This chimera was detected in approximately half of the investigated Stage IA non-small-cell lung cancer patients (44/104 cases, 42.3%). Although there was no significant difference in the overall survival rate between RUNX1-GLRX5-positive and -negative cases (P = 0.088), a significantly lower relapse rate was observed in the RUNX1-GLRX5-positive cases (P = 0.039), indicating that this chimera can be used as a biomarker for good prognosis in Stage IA patients. Detection of the RUNX1-GLRX5 chimeric transcript may therefore be useful for the determination of a postoperative treatment plan for Stage IA non-small-cell lung cancer patients.
authors.affiliation: Department of Respiratory Medicine, The University of Tokyo Hospital, Tokyo.
authors.forename: Rie
authors.initials: R
authors.lastname: Ishikawa
authors.affiliation: Department of Respiratory Medicine, The University of Tokyo Hospital, Tokyo.
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Amano
authors.affiliation: Department of Respiratory Medicine, The University of Tokyo Hospital, Tokyo.
authors.forename: Masanori
authors.initials: M
authors.lastname: Kawakami
authors.affiliation: Department of Respiratory Medicine, The University of Tokyo Hospital, Tokyo.
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Sunohara
authors.affiliation: Department of Respiratory Medicine, The University of Tokyo Hospital, Tokyo.
authors.forename: Kousuke
authors.initials: K
authors.lastname: Watanabe
authors.affiliation: Department of Respiratory Medicine, The University of Tokyo Hospital, Tokyo.
authors.forename: Hidenori
authors.initials: H
authors.lastname: Kage
authors.affiliation: Department of Respiratory Medicine, The University of Tokyo Hospital, Tokyo.
authors.forename: Nobuya
authors.initials: N
authors.lastname: Ohishi
authors.affiliation: Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yatomi
authors.affiliation: Department of Cardiothoracic Surgery, The University of Tokyo Hospital, Tokyo.
authors.forename: Jun
authors.initials: J
authors.lastname: Nakajima
authors.affiliation: Department of Pathology, The University of Tokyo Hospital, Tokyo, Japan.
authors.forename: Masashi
authors.initials: M
authors.lastname: Fukayama
authors.affiliation: Department of Respiratory Medicine, The University of Tokyo Hospital, Tokyo.
authors.forename: Takahide
authors.initials: T
authors.lastname: Nagase
authors.affiliation: Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo dtakai-ind@umin.ac.jp.
authors.forename: Daiya
authors.initials: D
authors.lastname: Takai
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry* / Q000473:pathology*; D002678:Chimera; D050676:Core Binding Factor Alpha 2 Subunit / Q000032:analysis*; D005260:Female; D054477:Glutaredoxins / Q000032:analysis*; D006801:Humans; D008175:Lung Neoplasms / Q000737:chemistry* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011184:Postoperative Period; D011237:Predictive Value of Tests; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D050676:Core Binding Factor Alpha 2 Subunit; C516011:GLRX5 protein, human; D054477:Glutaredoxins; C493728:RUNX1 protein, human
keywords: GLRX5; RUNX1; biological markers; gene fusion; non-small-cell lung cancer